Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by jocotocoon Nov 03, 2010 10:47am

323 Views

Post# 17650783

RE: Potential fly in the ointment?

Your the one that sounds hokey ..idiot. Do you work for BP? You think they can disconnent their mud line and run it into 5 gallon pails and count how many they fill in a minute. That's your flow test? A drill stem test on a multi zone deep well? You have to pack off each zone to be tested and use metering equipment . Very long procedure and you must maintain control the whole time.
This well has no issues . If the well had sat for months after drilling the might have to stimulate it abit...but with these pressures and flow expected...it's a beast doesn'r need any help.
Cheers
Jocotoco

Bullboard Posts

Visionstate set to leverage success in the U.S. market